Achyut Bora

Disrupting the Base Excision Repair (BER) Pathway by Targeting the Abasic Site Enhances the Sensitivity of PARP Inhibitor in HR-Proficient Cancer Cells Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPis) are clinically effective in homologous recombination (HR)-deficient cancers but have limited efficacy in HR-proficient cancers; therefore, new st...

Published: My recent research on PARP inhibitors in BRCA1/2-proficient cancers, featured in ACS Chemical Biology journal. #cancerresearch #dnadamage ACS Publications | @pubs.acs.org pubs.acs.org/doi/full/10....

I’ve finally successfully defended my PhD thesis and am now stepping into the next phase of my journey👨‍🎓🙂. I am grateful to everyone who has been a part of my journey🙏🙏 (CSIR-Indian Institute of Chemical Biology, Kolkata) #csir_iicb #AcSIR_India #PhD #Doctorate_Journey #Cancer_Biology #DDR

The research highlights targeting DNA abasic sites (loss of a base in dsDNA) to enhance the efficacy of temozolomide, a commonly used alkylating agent, in cancer treatment. #cancerresearch #abasic_sites #DNA_damage_response

Published our research work in the NAR Cancer Journal;

DNA abasic sites act as rational therapeutic targets to synergize temozolomide response in both MMR-proficient and deficient cancer
academic.oup.com/narcancer/ar...